Faculty Opinions recommendation of A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950602.793456017 ◽

2012 ◽

Author(s):

Francisco Cruz

Keyword(s):

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Adrenoceptor Agonist

Download Full-text

Faculty Opinions recommendation of A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950602.793455953 ◽

2012 ◽

Author(s):

Ariana Smith

Keyword(s):

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Adrenoceptor Agonist

Download Full-text

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder

European Urology ◽

10.1016/j.eururo.2012.05.053 ◽

2012 ◽

Vol 62 (5) ◽

pp. 834-840 ◽

Author(s):

Eliot H. Ohlstein ◽

Alexander von Keitz ◽

Martin C. Michel

Keyword(s):

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Adrenoceptor Agonist

Download Full-text

Faculty Opinions recommendation of A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950602.793455907 ◽

2012 ◽

Author(s):

Howard Goldman ◽

Alana M Murphy

Keyword(s):

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Adrenoceptor Agonist

Download Full-text

Faculty Opinions recommendation of A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950602.793465820 ◽

2012 ◽

Author(s):

Hashim Hashim ◽

Riyad Almousa

Keyword(s):

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Adrenoceptor Agonist

Download Full-text

Faculty Opinions recommendation of OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006591.793478312 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Quality Of Life ◽

Urinary Incontinence ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Overactive Bladder Symptoms ◽

Bladder Symptoms

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793482011 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793480560 ◽

2013 ◽

Author(s):

Howard Goldman ◽

Alana M Murphy

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Download Full-text

Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double‐blind, randomized placebo‐controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)

Neurourology and Urodynamics ◽

10.1002/nau.24552 ◽

2021 ◽

Author(s):

Sung Yong Cho ◽

Seong Jin Jeong ◽

Sangchul Lee ◽

Janghwan Kim ◽

Seong Ho Lee ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Overactive Bladder Symptoms ◽

Bladder Symptoms

Download Full-text

Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder

Urology ◽

10.1016/j.urology.2009.09.018 ◽

2010 ◽

Vol 75 (1) ◽

pp. 62-68 ◽

Author(s):

Roger R. Dmochowski ◽

Kenneth M. Peters ◽

Jon D. Morrow ◽

Zhonghong Guan ◽

Jason Gong ◽

...

Keyword(s):

Overactive Bladder ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Randomized, double-blind placebo-controlled trial with Bryophyllum pinnatum versus placebo for the treatment of overactive bladder in postmenopausal women

Phytomedicine ◽

10.1016/j.phymed.2012.10.007 ◽

2013 ◽

Vol 20 (3-4) ◽

pp. 351-358 ◽

Author(s):

Cornelia Betschart ◽

Ursula von Mandach ◽

Burkhardt Seifert ◽

David Scheiner ◽

Daniele Perucchini ◽

...

Keyword(s):

Overactive Bladder ◽

Postmenopausal Women ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Bryophyllum Pinnatum

Download Full-text